24/7 Live News Portal

AstraZeneca expects to start vaccine shipments to Latin America in 2021


FILE – In this Saturday, July 18, 2020, file photo, AstraZeneca’s name and corporate logo are displayed at its offices in Cambridge, England. (AP Photo / Alastair Grant, file)


Pharmaceutical AstraZeneca, which announced an agreement whereby Argentina and Mexico will produce the coronavirus vaccine, said that if the clinical trials are successful it will start shipments to Latin America in the first half of 2021.

In a statement, the pharmaceutical company highlighted the agreement signed with the Carlos Slim Foundation, of the Mexican billionaire, to contribute to the production in Argentina and Mexico and its distribution without economic benefit in Latin America, of the potential COVID-19 vaccine, AZD1222.

The firm said that the agreement “will initially provide 150 million doses in the region,” excluding Brazil, which will be covered by the agreement that the pharmaceutical company with the Brazilian government announced last June.

In addition, he recognized the urgency of the pandemic and said he will work in partnership with partners to supply the vaccine so that it is available in an equitable manner.

The firm said that it is working with strategic partners in the region including Argentina and Mexico, “taking advantage of their productive capacity” to facilitate the early availability of the potential vaccine.

“We are extremely satisfied to be part of an alliance with partners in Latin America where our sole objective is to provide rapid access to the potential vaccine in Mexico and throughout the Latin American region,” said Sylvia Varela, president and CEO of AstraZeneca Mexico.

While the Carlos Slim Foundation confirmed that it was joining the effort “for the production of the vaccine in Mexico and Argentina in order to start the supply to Latin America.”

He pointed out that if its efficacy and safety are proven and approved by health authorities, the vaccine would contribute decisively to prevent further loss of life and allow a return to normality.

A few days ago, Oxford University and AstraZeneca announced interim results of a phase I / II clinical trial in the UK that showed robust immune responses against the SARS-CoV2 virus in all participants.


This Thursday, in his morning conference every day, the president of Mexico, Andrés Manuel López Obrador, will announce the agreement in the company of health authorities and Foreign Minister Marcelo Ebrard.

“Tomorrow we will announce with the Secretary of Health (Jorge Alcocer) the agreements reached to produce in Mexico and Argentina, with crucial support from the Carlos Slim Foundation, between 150 and 250 million doses of the vaccine developed by AstraZeneca to deal with the Covid-19, ”Ebrard said in a message on Twitter.

While the undersecretary of Prevention and Health Promotion of Mexico and in charge of the strategy against the coronavirus in this country, Hugo López-Gatell, considered that he announced as “important news.”

The official asked the media for patience and said that on Thursday morning, together with Alcocer, he would accompany the president “to talk about vaccines in a panoramic way and about the opportunities that may arise in the case of Mexico.”

This day, the president of Argentina, Alberto Fernández, announced that his country, together with Mexico, will produce for Latin America the coronavirus vaccine developed by the AstraZeneca laboratory in collaboration with the British University of Oxford.

“We hope as soon as possible to start the production process,” Fernández said at a press conference, who minutes later contacted his Mexican counterpart, Andrés Manuel López Obrador.

The Argentine president stressed that this step will allow Latin American countries to access the vaccine at affordable prices, at a cost of between $ 3 and $ 4 per dose.